amgen

The filing of NDA for Abaloparatide-SC removes a key overhang on the shares of Radius Health Inc (NASDAQ: RDUS), according to Cantor Fitzgerald. Radius Health announced that it has submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for abaloparatide–SC 80...

Short interest in many of the leading biotech stocks shrank in the most recent period. However, two of the largest biotech companies bucked that trend in late January. Credit Suisse was bullish on both of them during the short interest period. While short sellers shied away from many...

Short interest moves in leading biotech stocks were mixed in the most recent period. However, Illumina, Inc. (NASDAQ: ILMN) and Baxalta Inc (NYSE: BXLT) saw sharp increases in their short interest in late November. Short sellers appeared to lose interest in Juno Lighting LLC (NASDAQ: JUNO) late in...

Short-sellers continued to be selective in the leading biotech stocks in the most recent period. Biogen and Medivation saw sharp drops in their short interest in early October. The number of Amgen shares short surged during that time. In the wake of ongoing market volatility and...

Short interest changes in biotech stocks were mixed during the most recent period. Baxalta Inc (NYSE: BXLT) and Juno Therapeutics Inc (NASDAQ: JUNO) saw short interest surges in late September. Short interest in Medivation Inc (NASDAQ: MDVN) plunged during that time. With the ongoing market...

Akebia Therapeutics Inc (NASDAQ: AKBA) is developing a safer treatment for anemia in patients with Chronic Kidney Disease. The compound, AKB-6548, is expected to go into Phase III clinical trials soon. AKB-6548 is an oral therapy designed to be both safer and easier to administer and will expand...

As market volatility continued after the August sell-off, short sellers moved on biotech stocks. Large cap biotechs Amgen, Celgene and Gilead Sciences saw surges in their short interest in early September. Short interest rose in nearly all of the leading biotech stocks in that time. With the...

Some of the biggest swings in short interest among the leading biotechs and emerging pharmaceuticals between the May 29 and June 15 settlement dates happened to Amgen, Inc. (NASDAQ: AMGN), Gilead Sciences, Inc. (NASDAQ: GILD) and Illumina, Inc. (NASDAQ: ILMN). Let's take a quick look at how these...

Ahead of the May 29 American Society of Clinical Oncology (ASCO) conference, analysts at Goldman Sachs reviewed the outlook for some of biotech's hottest names: Amgen, Inc. (NASDAQ: AMGN), Celgene Corporation (NASDAQ: CELG) and Clovis Oncology Inc (NASDAQ: CLVS). Goldman has Buy ratings on...

Short interest among leading biotechs and emerging pharmaceuticals increased nearly all across the board between February 13 and February 27. Leading the trend were BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Celgene Corporation (NASDAQ: CELG) and Vertex Pharmaceuticals Incorporated (NASDAQ:...

By and large, short interest among the leading biotechs and emerging pharmaceuticals reversed course and rose again between the January 30 and February 13 settlement dates. Leading that trend were Amgen, Inc. (NASDAQ: AMGN), Juno Therapeutics Inc (NASDAQ: JUNO) and Vertex Pharmaceuticals...